Amino Acids

, Volume 42, Issue 2–3, pp 803–811 | Cite as

A gold-containing drug against parasitic polyamine metabolism: the X-ray structure of trypanothione reductase from Leishmania infantum in complex with auranofin reveals a dual mechanism of enzyme inhibition

  • Andrea Ilari
  • Paola Baiocco
  • Luigi Messori
  • Annarita Fiorillo
  • Alberto Boffi
  • Marina Gramiccia
  • Trentina Di Muccio
  • Gianni Colotti
Open Access
Original Article


Auranofin is a gold(I)-containing drug in clinical use as an antiarthritic agent. Recent studies showed that auranofin manifests interesting antiparasitic actions very likely arising from inhibition of parasitic enzymes involved in the control of the redox metabolism. Trypanothione reductase is a key enzyme of Leishmania infantum polyamine-dependent redox metabolism, and a validated target for antileishmanial drugs. As trypanothione reductase contains a dithiol motif at its active site and gold(I) compounds are known to be highly thiophilic, we explored whether auranofin might behave as an effective enzyme inhibitor and as a potential antileishmanial agent. Notably, enzymatic assays revealed that auranofin causes indeed a pronounced enzyme inhibition. To gain a deeper insight into the molecular basis of enzyme inhibition, crystals of the auranofin-bound enzyme, in the presence of NADPH, were prepared, and the X-ray crystal structure of the auranofin–trypanothione reductase–NADPH complex was solved at 3.5 Å resolution. In spite of the rather low resolution, these data were of sufficient quality as to identify the presence of the gold center and of the thiosugar of auranofin, and to locate them within the overall protein structure. Gold binds to the two active site cysteine residues of TR, i.e. Cys52 and Cys57, while the thiosugar moiety of auranofin binds to the trypanothione binding site; thus auranofin appears to inhibit TR through a dual mechanism. Auranofin kills the promastigote stage of L. infantum at micromolar concentration; these findings will contribute to the design of new drugs against leishmaniasis.


Gold Auranofin Leishmania Trypanothione reductase 







Glutathione reductase


4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid


3-[4.5-dimethylthiazol-2-yl]-2.5-diphenyltetrazolium bromide


Reduced nicotinamide adenine dinucleotide


Reduced nicotinamide adenine dinucleotide phosphate


Reactive oxygen species


Trypanothione reductase


Thioredoxin reductase


Trypanothione synthatase


Trypanothione disulfide


Trypanothione (N1-N8-bis(glutathionyl)spermidine


Leishmania parasites depend on spermidine for growth and survival. They synthesize polyamines and polyamine precursors, and also scavenge them from their microenvironment, using specific transporters. In addition, Leishmania spp. possess a unique thiol-based, polyamine-based metabolism, in which trypanothione (N1-N8-bis(glutathionyl)spermidine, T(SH)2) and trypanothione reductase (TR) replace many of the antioxidant and metabolic functions of the glutathione/glutathione reductase (GR) and thioredoxin/thioredoxin reductase (TrxR) systems present in the host (Colotti and Ilari 2011; Cunningham and Fairlamb 1995; Fairlamb et al. 1985).

Consequently, the enzymes involved in spermidine synthesis and its utilization, i.e. arginase, ornithine decarboxylase, S-adenosylmethionine decarboxylase, spermidine synthase, tryparedoxins, tryparedoxin-dependent peroxidases and, in particular, trypanothione synthetase (TryS) and TR, are targets for drug development (Colotti and Ilari 2011).

TryS and TR are necessary for Leishmania survival, protecting the parasite from oxidative damage and toxic heavy metals, and allowing the delivery of the reducing equivalents for DNA synthesis. The known sensitivity of Leishmania toward reactive oxygen species (ROS) and the absence of the trypanothione/TR system in the mammalian host make TryS and TR promising targets for the development of parasite-specific drugs.

TR, as most enzymes involved in the polyamine metabolism in Leishmania, contains cysteine residues in the active site, and can be inhibited by metal-containing compounds. For instance, antimonial drugs, which are used against leishmaniasis since 1940s (Goodwin and Page 1943), although suffering from high toxicity and increasing resistance, interfere in vivo with the T(SH)2 metabolism by inducing rapid efflux of intracellular T(SH)2, and inhibit TR in intact cells (Cunningham and Fairlamb 1995). We disclosed the molecular mechanism of antimonial inhibition of TR by structural analysis of reduced TR in complex with reduced nicotinamide adenine dinucleotide phosphate (NADPH) and Sb(III) (Baiocco et al. 2009a). This structure revealed that the two redox-active catalytic cysteine residues (Cys52 and Cys57), one threonine residue (Thr335) and His461’ of the twofold symmetry related subunit in the dimer are engaged in complex formation with Sb(III). Other metal compounds, such as silver, palladium and platinum derivatives, were reported to inhibit TR (Baiocco et al. 2011; Bonse et al. 2000; Otero et al. 2006).

Auranofin (AF) is a gold complex largely used in the clinics as an antiarthritic drug. It consists of a gold(I) center linearly coordinated to triethylphosphine and to 3,4,5 triacetyloxy-6-(acetyloxymethyl)oxane-2-thiolate, a thiosugar (Fig. 1). Detachment of the latter results into drug activation. Quite recently, a few studies revealed that auranofin might be conveniently employed for a number of different therapeutic indications (Fonteh et al. 2010; Kast 2010; Kean and Kean 2008; Navarro et al. 2010; Prast-Nielsen et al. 2010). In particular, it was shown that the gold(I) center of AF, being markedly thiophilic, manifests a high affinity for dithiol motifs, often present in the active site of some crucial parasitic enzymes. In view of this property it was proposed that auranofin might be tested as an antiparasitic agent.
Fig. 1

a Chemical structure of auranofin (AF); b chemical structure of Chloro(triethylphosphine)gold(I) (CTPAu)

Since AF induces strong inhibition of parasite growth for Plasmodium falciparum and for Schistosoma mansoni through the inhibition of thiol-dependent redox enzymes such as thioredoxin reductase and thioredoxin glutathione reductase (Angelucci et al. 2009; Kuntz et al. 2007; Sannella et al. 2008), we decided to explore whether AF might be used as an antileishmanial agent, in in vitro tests of growth inhibition of promastigotes from L. infantum and L. major species.

To corroborate these hypotheses, auranofin was challenged in vitro against trypanothione reductase, an important target of Leishmania, essential for trypanosomatids, to test its ability of inhibiting the enzyme. We also obtained crystal reduced TR from L. infantum in complex with NADPH and AF, thus demonstrating the mechanism of TR inhibition by gold derivatives.

In addition, since compounds such as gold(I) triphenylphosphine have a potent antiproliferative effect on Leishmania spp. and Trypanosoma cruzi, due to the reduced nicotinamide adenine dinucleotide (NADH) fumarate reductase inhibition (Vieites et al. 2009), we measured the ability of Chloro(triethylphosphine)gold(I) (CTPAu), i.e. a very soluble variant of AF (Fig. 1), which lacks the thiosugar moiety, to inhibit TR.


TR inhibition assay

TR activity was measured at 25°C in a diode array Hewlett-Packard HP8452A spectrophotometer as previously described (Baiocco et al. 2009a). Experiments for calculation of the Ki values were carried out by varying AF and CTPAu concentration. In a cuvette, 40 mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES) pH 7.5, 50 mM NaCl, 100 μM NADPH, 40 nM TR and the gold derivatives were allowed to equilibrate for 2 min at 25°C immediately prior the addition of trypanothione disulfide (TS2). Assays were initiated by addition of TS2 and the absorbance decrease at 340 nm, which indicates the oxidation of NADPH, was followed. The concentrations of NADPH was calculated using the extinction coefficient of a ε = 6,222 M−1 cm−1 at 340 nm. Trypanothione disulfide (Bachem) and NADPH (Sigma) were used for the experiments. Auranofin was purchased from Vinci Biochem and CTPAu from Sigma Chemical Company.

X-ray structure determination

Crystallization of TR from Leishmania infantum was carried out as reported previously (Baiocco et al. 2009b).

Crystals of the native oxidized form of TR were soaked for 1 h with a stabilizing solution of 2.5 M ammonium sulfate, 0.1 M Tris pH 8.5 containing 2 mM AF and 5 mM NADPH. Crystals were cryo-protected in a solution containing 75% v/v of the reservoir solution and 25% v/v of glycerol.

Single wavelength data set (λ = 0.918 Å) was collected at the beamline ID 14-1 at the synchrotron radiation source ESRF in Grenoble, France, using a CCD detector at a temperature of 100 K.

The data set was processed with DENZO (Otwinowski and Minor 1997) and scaled with SCALEPACK (Otwinowski and Minor 1997). The crystals belong to the P41 space group with the following cell dimensions: a = 103.05 Å, b = 103.05 Å, c = 191.6 Å. Crystal parameters and complete data collection statistics are given in Table 1.
Table 1

Crystal parameters, data collection and refinement statistics

Data collection


Space group


Unit cell dimension (Å)

a = 103.58, b = 103.58, c = 191.60

Resolution range (Å)

50–3.50 (3.63–3.5)

Total reflections


Unique reflections


Completeness (%)

100 (100)


0.17 (0.50)


6.4 (6.4)


9.4 (1.9)

Refinement statistics

 Resolution range (Å)

50.0–3.5 (3.59–3.50)

 Free R value (%)

31.9 (41.3)

 R value (working set) (%)

26.7 (39.7)

 RMS bonds (Å)


 RMS angles (°)


Ramachandran analysis

 Residues in most favoured regions (%)


 Residues in allowed regions (%)


 Outliers (%)


Values in parentheses are for the highest resolution shell

Rmerge = ΣhklΣi |Ii(hkl) − <I(hkl)>|/ΣhklΣi Ii(hkl) where Ii(hkl) is the ith observation of the reflection (hkl) and <I(hkl)> is the mean intensity of the (hkl) reflection

The structure of L. infantum TR in complex with AF and NADPH was solved by molecular replacement using as search model the native TR (pdb code 2JK6) with the program Molrep (Vagin and Teplyakov 1997). Refinement was performed using the program REFMAC5 (Murshudov et al. 1997) and model building was carried out using the program COOT (Emsley and Cowtan 2004). The final Rcrys for all resolution shells (50–3.5 Å), calculated using the working set reflections (22593), is 26.7% and the free R value, calculated using the test set reflections (1291), is 31.9%. The final model is a dimer that contains 976 residues (488 for monomer A and 488 for monomer B), two FAD molecules, two NADPH molecules, two gold ions, two chloride ions, two (3,4,5 triacetyloxy-6-(acetyloxymethyl) oxane-2-thiolate thiosugars, and two sulphate ions (Schuettelkopf and van Aalten 2004). The most favored regions of the Ramachandran plot contain 92.2% of residues. The atomic coordinates and structure factors have been deposited in the Protein Data Bank with the PDB code 2YAU.

Parasite strains and promastigote assays

Promastigote stage of L. infantum strain MHOM/TN/80/IPT1 and L. major strain MHOM/SU/73/5-ASKH were used in drug susceptibility assays. Promastigotes were grown in Schneider’s Drosophila medium (SIGMA) containing 10% Fetal Calf Serum (FCS) (GIBCO-BRL) and 2% gentamicine (50 mg/L) (Sigma) at 22°C. The effect on cell growth was analyzed incubating an initial concentration of 1 × 106 parasites/mL with various concentrations of the compounds.

Briefly, a 200 μL volume of suspension was seeded in triplicate in 96-well flat-bottom microtrays and incubated with different concentration of two gold compounds (AF and CTPAu): 50, 40, 30, 25, 20, 15, 10, 7.5, 5, 2.5, 1.25 μM. Antimonial compound was used as the reference anti-Leishmania drug. Each experiment was carried out in triplicate for each concentration. After 72 h of incubation, 40 μL of MTT (3-[4.5-dimethylthiazol-2-yl]-2.5-diphenyltetrazolium bromide) was added to each well and plates were further incubated for 2 h. The absorbance at 490 nm was measured with a 96-well scanner. Two independent experiments in triplicate were performed. In addition, the promastigote vitality was followed by microscopic observation after 72 h. Dose–response curves were recorded and the 50% inhibitory concentration (IC50) values were determined by GraphPad Prism 5.


At first, we explored whether AF might behave as an inhibitor of TR. Steady state condition kinetic experiments were carried out at various concentration of TS2 and inhibitor. After starting the reaction by the addition of TS2, the absorbance decrease at 340 nm, which indicates the oxidation of NADPH, was measured. Although a few traces (Fig. 2a, b) show a complex behavior, possibly due to auranofin modification, AF has a clear inhibitory effect on TR. Addition of increasing amount of AF resulted into remarkable enzyme inhibition, with a Ki value of 155 ± 35 nM, about 10 times lower than Sb(III) (Baiocco et al. 2009a), in the conditions tested (Fig. 2). CTPAu has a even higher inhibitory activity on TR, with a Ki of 18 ± 7 nM (Fig. 2).
Fig. 2

Inhibition of TR by AF and CTPAu. ad Oxidation kinetics of NADPH (100 μM) in the presence of 40 nM TR and of different concentrations of AF and TS2, measured at 340 nm. [TS2] a 50 μM; b 100 μM; c 200 μM; d 400 μM. [AF] traces in a 0, 20, 40, 100, 120, 250, 500 nM, 1, 5 μM; traces in b 0, 50, 120, 200, 500 nM, 1, 2, 10 μM; traces in c 0, 50, 100, 200, 500 nM, 1, 2, 10 μM; traces in d: 0, 50, 100, 200, 400 nM, 1, 2, 5, 10 μM. e Lineweaver–Burk plot and f Dixon plot of TR inhibition by auranofin. efilled squares [AF] = 0; open squares [AF] = 50 nM; filled circles [AF] = 100 nM; open circles [AF] = 200 nM. ffilled squares [TS2] = 50 μM; open squares [TS2]=100 μM; filled circles [TS2] = 200 μM; open circles [TS2] = 400 μM. g Lineweaver–Burk plot and h Dixon plot of TR inhibition by CTPAu. gfilled squares [CTPAu] = 0; open squares [CTPAu] = 10 nM; filled circles [CTPAu] = 25 nM; open circles [CTPAu] = 40 nM; filled triangles [CTPAu] = 60 nM; open triangles [CTPAu] = 100 μM. hopen squares [TS2] = 100 μM; open circles [TS2]=200 μM

To unveil the structural basis of enzyme inhibition, we tried to prepare crystals of the AF-inhibited enzyme that could be suitable for X-ray diffraction analysis. Several attempts were made based on co-crystallization, but all of these failed, since no crystals of crystallographic quality were obtained. Crystals of reduced TR in complex with NADPH and AF of reasonable crystallographic quality were in turn obtained by soaking crystals of oxidized TR for 1 h with a stabilizing solution of 2.5 M ammonium sulfate, 0.1 M Tris pH 8.5 containing 2 mM AF and 5 mM NADPH. These crystals were used to solve the structure TR in complex with AF at 3.5 Å resolution.

In spite of the fact that the resolution is rather low, diffraction data were sufficient to delineate the overall protein structure, which is practically superposable (RMSD about 0.5 Å) to those obtained for the Sb(III)-bound and the silver-bound TR structures (Baiocco et al. 2009a, 2011) (Fig. 3). A very clear electron density in the Fo-Fc map was found in both subunits, accounting for the presence of gold ions nearby the catalytic site, namely Cys52, Cys57 and His461’ with an occupancy of 40% for both subunits (Fig. 4a).
Fig. 3

X-ray structure of the Au(I)-TR complex A. Overall structure. The two subunits in the asymmetric unit are colored in red and in blue, respectively. The trypanothione binding cavities are indicated by arrows and the thiosugar moiety is indicated in CPK. The picture is generated in PyMol (DeLano 2008)

Fig. 4

a Au(I) binding site. The gold and the chloride ions are indicated in orange and green, respectively. The anomalous difference Fourier map for data collected at the gold peak wavelength is shown at a 5σ contour level in green. b Trypanothione binding site. The Cys52, Cys57, Thr335, His461′, Glu466′ residues, the FAD molecule and the thiosugar moiety are represented as sticks. The pictures have been generated in PyMol (DeLano 2008)

In addition, the inspection of the electronic density map allowed us to identify the thiosugar moiety of AF in the active site of TR with an occupancy of 70% (Fig. 4b). The Fo-Fc electronic density map contoured at 3.0 Å indicates the presence of an additional conformation with low occupancy.

As shown in the Fig. 4a, Au(I) is coordinated by three ligands. The two cysteine residues of the active site (Cys52 and Cys57), are bound to the Au(I) ion with distances SGCys52–Au = 2.1 Å and SGCys57–Au = 2.1 Å, respectively. The third ligand is a chloride ion, placed at a distance of 2.5 Å from Au(I). Thus, in the auranofin–TR complex the gold ion displays a planar-trigonal coordination, where the ligands are the two cysteine residues and a chloride ion, one of the principal coordination geometries of the d10 closed-shell-configuration Au(I) (Shaw 1999).

The 3,4,5-triacetyloxy-6-(acetyloxymethyl)oxane-2-thiolate thiosugar is bound at the trypanothione binding site, and forms contacts with the chloride ion and with two important residues of TR, His461′ and Glu466′, belonging to the second subunit of the dimer, which activate Cys52 similarly to serine and cysteine proteases during trypanothione reduction (Fig. 4b). The distance between the sulphur atom of the thiosugar and the chloride is 3.1 Å, while the acetate groups of the thiosugar are at distances of about 3 Å from His461′, Glu466′ and Glu467′. In particular, the oxygen atoms of the acetate groups are 2.9 Å away from the nitrogen NE2 of His461′, 3.1 Å apart from the carboxyl group of Glu466′, and at 3.3 Å from the carboxyl group of Glu467’. Therefore, AF blocks the two cysteine residues of the active site, and does not allow binding of trypanothione to His461′, belonging to the catalytic triad of TR, and to Glu466′, which stabilizes the His461′ positive charge during the redox reaction catalysed by TR.

The possible use of AF as antileishmanial drug was tested by promastigote growth inhibition assays.

Both AF and CTPAu induced a dose-dependent anti-proliferative effect on promastigotes, the extracellular Leishmania stage of both L. infantum and L. major species. A dose of 50 μM of either gold compounds induced 100% promastigote mortality, whereas concentrations <40 μM determined a leishmanistatic activity, with different rates of inhibition activity of two Leishmania species. At these sub-lethal concentrations, parasites showed motility inhibition and body swelling, not present in control cells. Lower concentrations, ≤2.5 μM, did not affect either promastigote growth or morphology. The IC50 values deduced from the dose–response curve are different for the two compounds (Table 2). AF produced a higher leishmanistatic activity than CTPAu against both Leishmania species. Indeed, the auranofin IC50 was 9.68 ± 1.02 μM for L. infantum and 15.66 ± 1.24 μM for L. major, whereas the CTPAu IC50 showed slightly higher values, i.e. 16.59 ± 1.03 μM for L. infantum and 17.48 ± 1.02 μM for L. major.
Table 2

Activity of auranofin and CTPAu against Leishmania parasites


L. infantum

L. major


9.68 ± 1.02

15.66 ± 1.24


16.59 ± 1.03

17.48 ± 1.02

Results are expressed as IC50 (μM) ± standard error


The experiments presented in the present work show that auranofin, a drug used against rheumatoid arthritis, is able to inhibit with a dual mechanism the trypanothione reductase, a key enzymes of the polyamine metabolism in Leishmania, thereby killing the Leishmania parasites.

The available treatments for leishmaniasis are far from ideal. The traditional first-line treatment relies on pentavalent antimonials. Amphotericin B, the aromatic diamidine pentamidine and, more recently, miltefosine, are often effective, though they also have severe side effects.

With the exception of antimonials, the use of metal-containing drugs as antileishmanial agents has not been deeply explored up to now, although the emergence of drug-resistant strains of Leishmania warrants screening of new compounds and rational drug design.

Metals are often considered not selective. However, a few studies show promising results against the parasite. For example, zinc sulfate was tested clinically against cutaneous leishmaniasis, with cure rates >96.0% (Minodier and Parola 2007). Platinum-based DNA intercalators inhibit growth of Leishmania parasites (Lowe et al. 1999; Visbal et al. 2008), also displaying inhibitory activity versus metabolically important enzymes. A gold(I)-based complex with the bioactive coligand pyridine-2-thiol N-oxide shows inhibition of NADH fumarate reductase, a kinetoplastid parasite-specific enzyme absent in the host (Visbal et al., 2008), while gold(III) derivatives as [Au(dppz)2]Cl3 and Au(III) cyclometallated complexes are DNA intercalators with antileishmanial activity, the latter inhibiting different cysteine proteases in Trypanosoma and Leishmania (Fricker et al. 2008; Navarro et al. 2007).

These results prompted us to study the possibility of using AF, a gold(I)-containing drug, with known pharmacokinetics and pharmacodynamics, against leishmaniasis.

Auranofin (Ridaura), gold sodium thiomalate and aurothioglucose (Solganal) are gold-containing chemicals used in treating rheumatoid arthritis. In patients with inflammatory arthritis, such as adult and juvenile rheumatoid arthritis, gold salts decrease the inflammation of the joint lining and also prevent the inflammation from destroying the bone and cartilage surrounding the joint. Because they prevent destruction of joints (in contrast to antiinflammatory drugs that just treat symptoms and signs of arthritis but do not prevent the destruction) AF is known as a disease-modifying antirheumatic drug (DMARD) (Rau 2005). Chrysotherapy is also considered for cancer (Marzano et al. 2007; Shaw 1999).

The mechanism of action of AF is not fully known; gold is taken up by macrophages, which results in inhibition of phagocytosis and lysosomal membrane stabilization; other actions observed are decreased serum rheumatoid factor and alterations in immunoglobulins. Additionally, complement activation is decreased, prostaglandin synthesis is inhibited, and lysosomal enzyme activity is decreased (Bondeson 1997; Haynes et al. 1988).

In addition, AF and other gold-containing drugs are strong inhibitors of protozoan thioredoxin glutathione reductase and of mammalian thioredoxin reductases (Gromer et al. 1998; Kuntz et al. 2007). Notably, inhibition of these reductases is associated with important modifications of the intracellular redox balance and, in particular, with induction of severe oxidative stress and relevant cytotoxic effects in vitro (Lu et al. 2007; Yoo et al. 2006).

Since Leishmania effectively avoids the humoral branch of the host immune system by infecting preferentially the macrophage as amastigote, the preferential uptake of AF by the macrophages is of particular importance for treatment of leishmaniases, and should make the drug more effective and specific against the parasite.

AF inhibits TR from L. infantum with a Ki of 155 ± 35 nM, while the inhibition constant measured for Sb(III) is 1.5 μM: another gold(I) derivative, CTPAu, a very soluble variant of AF, lacking its thiosugar moiety, inhibits TR with a Ki of 18 ± 7 nM. Therefore, Au(I)-containing drugs are more effective than antimony in vitro. Recently, inhibition constants for Ag(0) and Ag(I) of 500 and 50 nM, respectively, were measured on TR (Baiocco et al. 2011). Therefore, Au(I)-containing compounds are very effective TR inhibitors.

The structural analysis of the crystal of reduced L. infantum TR in complex with NADPH and AF, solved at 3.5 Å resolution, demonstrates that the mechanism of inhibition is only partly similar to that of Sb(III). In fact the structure inspection clearly show that upon TR reduction by NADPH, Au(I) binds to the two cysteines Cys52 and Cys57 with a planar triangular coordination involving also a chloride ion, while both Sb(III) and silver bind the three residues of the catalytic triad (Cys52, Cys57 and His461′) of the enzyme.

In addition, although the relatively low resolution of the structure impairs a deeper analysis, the 3,4,5-triacetyloxy-6-(acetyloxymethyl)oxane-2-thiolate thiosugar of AF clearly occupies the trypanothione binding site, thus impairing substrate binding and engaging in hydrogen bond interactions both His461′ and Glu466′, that are involved in Cys52 activation during catalysis (Baiocco et al. 2009a; Karplus and Schulz 1989). AF therefore inhibits TR with a dual mechanism, i.e. by blocking both binding and reduction of oxidized trypanothione by TR.

These results are confirmed by in vitro experiments on L. infantum promastigotes, which showed that AF is able to kill the parasite at micromolar concentrations.

For these reasons, the authors believe that the use of gold-containing compounds represents a reasonable approach for the optimization of therapeutic strategies against leishmaniasis.


In the structures of TR in complex with NADPH and AF, as for those with Sb(III) or silver (Baiocco et al. 2009a, 2011), the metal ion is tightly bound to two cysteine groups in the active site of the enzyme, thereby disallowing the hydride transfer from the protein to the trypanothione. In addition, the thiosugar of auranofin contributes to TR inhibition by occupying the trypanothione binding site of TR.

This finding, and the works reporting that, in addition to gold derivatives, also silver, palladium and platinum derivatives, were reported to inhibit TR (Baiocco et al. 2011; Bonse et al. 2000; Otero et al. 2006), suggest that thiophilic metals that are Lewis soft acids, more generally, may serve as strong inhibitors of TR and may result in potential interest as antileishmanial agents.

The structural studies were independently supported by enzyme inhibition data for AF and CTPAu.

Such metal-dependent inhibition of thiol reductases opens the way to combined metal therapy of leishmaniasis. In view of these results we can state that AF behaves as a relatively strong inhibitor of TR and is endowed of antileishmanial activity in the micromolar range of concentration.

Studies are in progress to evaluate comparative enzyme inhibition by a series of structurally different gold complexes.



We acknowledge the European Synchrotron Radiation Facility (Grenoble, France) for provision of synchrotron radiation at beamline ID 14-1 and PRIN2007 to GC. We thank Dr. Francesco Angelucci and Dr. Veronica Morea for useful comments.


  1. Angelucci F, Sayed AA, Williams DL, Boumis G, Brunori M, Dimastrogiovanni D, Miele AE, Pauly F, Bellelli A (2009) Inhibition of Schistosoma mansoni thioredoxin-glutathione reductase by auranofin: structural and kinetic aspects. J Biol Chem 284(42):28977–28985PubMedCrossRefGoogle Scholar
  2. Baiocco P, Colotti G, Franceschini S, Ilari A (2009a) Molecular basis of antimony treatment in leishmaniasis. J Med Chem 52:2603–2612PubMedCrossRefGoogle Scholar
  3. Baiocco P, Franceschini S, Ilari A, Colotti G (2009b) Trypanothione reductase from Leishmania infantum: cloning, expression, purification, crystallization and preliminary X-ray data analysis. Protein Peptide Lett 16(2):196–200CrossRefGoogle Scholar
  4. Baiocco P, Ilari A, Ceci P, Orsini S, Gramiccia M, Di Muccio T, Colotti G (2011) Inhibitory effect of silver nanoparticles on trypanothione reductase activity and Leishmania infantum proliferation. ACS Med Chem Lett 2(3):230–233CrossRefGoogle Scholar
  5. Bondeson J (1997) The mechanisms of action of disease-modifying antirheumatic drugs: a review with emphasis on macrophage signal transduction and the induction of proinflammatory cytokines. Gen Pharmacol 29(2):127–150PubMedCrossRefGoogle Scholar
  6. Bonse S, Richards JM, Ross SA, Lowe G, Krauth-Siegel RL (2000) (2,2’:6’,2”-Terpyridine)platinum(II) complexes are irreversible inhibitors of Trypanosoma cruzi trypanothione reductase but not of human glutathione reductase. J Med Chem 43:4812–4821PubMedCrossRefGoogle Scholar
  7. Colotti G, Ilari A (2011) Polyamine metabolism in Leishmania: from arginine to trypanothione. Amino Acids 40(2):269–285PubMedCrossRefGoogle Scholar
  8. Cunningham ML, Fairlamb AH (1995) Trypanothione reductase from Leishmania donovani. Purification, characterisation and inhibition by trivalent antimonials. Eur J Biochem 230:460–468PubMedCrossRefGoogle Scholar
  9. DeLano WL (2008) The PyMOL molecular graphics system. DeLano Scientific LLC, Palo AltoGoogle Scholar
  10. Emsley P, Cowtan K (2004) Coot: model-building tools for molecular graphics. Acta Crystallogr D Biol Crystallogr 60:2126–2132PubMedCrossRefGoogle Scholar
  11. Fairlamb AH, Blackburn P, Ulrich P, Chait BT, Cerami A (1985) Trypanothione: a novel bis(glutathionyl)spermidine cofactor for glutathione reductase in trypanosomatids. Science 227:1485–1487PubMedCrossRefGoogle Scholar
  12. Fonteh PN, Keter FK, Meyer D (2010) HIV therapeutic possibilities of gold compounds. Biometals 23(2):185–196PubMedCrossRefGoogle Scholar
  13. Fricker SP, Mosi RM, Cameron BR, Baird I, Zhu Y, Anastassov V, Cox J, Doyle PS, Hansell E, Lau G, Langille J, Olsen M, Qin L, Skerlj R, Wong RS, Santucci Z, McKerrow JH (2008) Metal compounds for the treatment of parasitic diseases. J Inorg Biochem 102(10):1839–1845PubMedCrossRefGoogle Scholar
  14. Goodwin LG, Page JE (1943) A study of the excretion of organic antimonials using a polarographic procedure. Biochem J 22:236–240Google Scholar
  15. Gromer S, Arscott LD, Williams CH Jr, Schirmer RH, Becker K (1998) Human placenta thioredoxin reductase. Isolation of the selenoenzyme, steady state kinetics, and inhibition by therapeutic gold compounds. J Biol Chem 273:20096–20101PubMedCrossRefGoogle Scholar
  16. Haynes DR, Garrett IR, Vernon-Roberts B (1988) Effect of gold salt treatment on the receptor binding activity of monocytes and macrophages isolated from rats with adjuvant arthritis. Rheumatol Int 8(4):159–164PubMedCrossRefGoogle Scholar
  17. Karplus PA, Schulz GE (1989) Substrate binding and catalysis by glutathione reductase as derived from refined enzyme: substrate crystal structures at 2 Å resolution. J Mol Biol 210:163–180PubMedCrossRefGoogle Scholar
  18. Kast RE (2010) Glioblastoma invasion, cathepsin B, and the potential for both to be inhibited by auranofin, an old anti-rheumatoid arthritis drug. Cent Eur Neurosurg 71(3):139–142CrossRefGoogle Scholar
  19. Kean WF, Kean IR (2008) Clinical pharmacology of gold. Inflammopharmacol 16(3):112–125CrossRefGoogle Scholar
  20. Kuntz AN, Davioud-Charvet E, Sayed AA, Califf LL, Dessolin J, Arnér ES, Williams DL (2007) Thioredoxin glutathione reductase from Schistosoma mansoni: an essential parasite enzyme and a key drug target. PLoS Med 4(6):e206PubMedCrossRefGoogle Scholar
  21. Lowe G, Droz AS, Vilaivan T, Weaver GW, Tweedale L, Pratt JM, Rock P, Yardley V, Croft SL (1999) Cytotoxicity of (2,2’:6’,2’’-terpyridine)platinum(II) complexes to Leishmania donovani, Trypanosoma cruzi, and Trypanosoma brucei. J Med Chem 42:999–1006PubMedCrossRefGoogle Scholar
  22. Lu J, Chew EH, Holmgren S, Targeting A (2007) TrxR is a basis for cancer therapy by arsenic trioxide. Proc Natl Acad Sci USA 104:12288–12293PubMedCrossRefGoogle Scholar
  23. Marzano C, Gandin V, Folda A, Scutari G, Bindoli A, Rigobello MP (2007) Inhibition of thioredoxin reductase by auranofin induces apoptosis in cisplatin-resistant human ovarian cancer cells. Free Radic Biol Med 42(6):872–881PubMedCrossRefGoogle Scholar
  24. Minodier P, Parola P (2007) Cutaneous leishmaniasis treatment. Travel Med Infect Dis 5:150–158PubMedCrossRefGoogle Scholar
  25. Murshudov GN, Vagin AA, Dodson EJ (1997) Refinement of macromolecular structures by the maximum-likelihood method. Acta Crystallogr D Biol Crystallogr 53:240–255PubMedCrossRefGoogle Scholar
  26. Navarro M, Hernández C, Colmenares I, Hernández P, Fernández M, Sierraalta A, Marchán E (2007) Synthesis and characterization of [Au(dppz)2]Cl3. DNA interaction studies and biological activity against Leishmania (L.) mexicana. J Inorg Biochem 101(1):111–116PubMedCrossRefGoogle Scholar
  27. Navarro M, Gabbiani C, Messori L, Gambino D (2010) Metal-based drugs for malaria, trypanosomiasis and leishmaniasis: recent achievements and perspectives. Drug Discov Today 15(23–24):1070–1078PubMedCrossRefGoogle Scholar
  28. Otero L, Vieites M, Boiani L, Denicola A, Rigol C, Opazo L, Olea-Azar C, Maya JD, Morello A, Krauth-Siegel RL, Piro OE, Castellano E, Gonzalez M, Gambino D, Cerecetto H (2006) Novel antitrypanosomal agents based on palladium nitrofurylthiosemicarbazone complexes: DNA and redox metabolism as potential therapeutic targets. J Med Chem 49:3322–3331PubMedCrossRefGoogle Scholar
  29. Otwinowski Z, Minor W (1997) Processing of X-ray diffraction data collected in oscillation mode. Methods Enzymol 276:307–326CrossRefGoogle Scholar
  30. Prast-Nielsen S, Cebula M, Pader I, Arnér ES (2010) Noble metal targeting of thioredoxin reductase—covalent complexes with thioredoxin and thioredoxin-related protein of 14 kDa triggered by cisplatin. Free Radic Biol Med 49(11):1765–1778PubMedCrossRefGoogle Scholar
  31. Rau R (2005) Have traditional DMARDs had their day? Effectiveness of parenteral gold compared to biologic agents. Clin Rheumatol 24:189–202PubMedCrossRefGoogle Scholar
  32. Sannella AR, Casini A, Gabbiani C, Messori L, Bilia AR, Vincieri FF, Majori G, Severini C (2008) New uses for old drugs. Auranofin, a clinically established antiarthritic metallodrug. exhibits potent antimalarial effects in vitro: mechanistic and pharmacological implications. FEBS Lett 582(6):844–847PubMedCrossRefGoogle Scholar
  33. Schuettelkopf AW, van Aalten DMF (2004) PRODRG: a tool for high-throughput crystallography of protein-ligand complexes. Acta Crystallogr D 60:1355–1363Google Scholar
  34. Shaw CF (1999) Gold-based therapeutic agents. Chem Rev 99:2589–2600CrossRefGoogle Scholar
  35. Vagin A, Teplyakov A (1997) MOLREP: an automated program for molecular replacement. J Appl Cryst 30:1022–1025CrossRefGoogle Scholar
  36. Vieites M, Smircich P, Buggeri L, Marchán E, Gómez-Barrio A, Navarro M, Garat B, Gambino D (2009) Synthesis and characterization of a pyridine-2-thiol N-oxide gold(I) complex with potent antiproliferative effect against Trypanosoma cruzi and Leishmania sp. insight into its mechanism of action. J Inorg Biochem 103:1300–1306PubMedCrossRefGoogle Scholar
  37. Visbal G, Marchán E, Maldonado A, Simoni Z, Navarro M (2008) Synthesis and characterization of platinum-sterol hydrazone complexes with biological activity against Leishmania (L.) mexicana. J Inorg Biochem 102(3):547–554PubMedCrossRefGoogle Scholar
  38. Yoo MH, Xu XM, Carlson BA, Gladyshev VN, Hatfield DL (2006) Thioredoxin reductase 1 deficiency reverses tumor phenotype and tumorigenicity of lung carcinoma cells. J Biol Chem 281:13005–13008PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2011

Authors and Affiliations

  • Andrea Ilari
    • 1
  • Paola Baiocco
    • 1
  • Luigi Messori
    • 2
  • Annarita Fiorillo
    • 1
  • Alberto Boffi
    • 1
  • Marina Gramiccia
    • 3
  • Trentina Di Muccio
    • 3
  • Gianni Colotti
    • 1
  1. 1.Department of Biochemical Sciences, Institute of Molecular Biology and Pathology CNRSapienza University of RomeRomeItaly
  2. 2.Department of ChemistryUniversity of FlorenceSesto FiorentinoItaly
  3. 3.Dipartimento di Malattie Infettive, Parassitarie e ImmunomediateIstituto Superiore di SanitàRomeItaly

Personalised recommendations